Pharvaris BV (PHVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharvaris BV (PHVS) has a cash flow conversion efficiency ratio of -0.126x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.80 Million) by net assets ($300.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Pharvaris BV (PHVS) total market value for the company's overall valuation and market capitalisation.
Pharvaris BV - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Pharvaris BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pharvaris BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharvaris BV ranked by their cash flow conversion efficiency. See Pharvaris BV cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyundai Mar&Fi
KO:001450
|
0.051x |
|
Denison Mines Corp
TO:DML
|
-0.136x |
|
Suzhou Nanomicro Technology Co Ltd
SHG:688690
|
0.014x |
|
Anhui Conch Cement Company Limited
F:AQE
|
0.015x |
|
President Securities Corp
TW:2855
|
-0.017x |
|
Acer Incorporated
F:AC5G
|
0.017x |
|
Dynex Capital Inc
NYSE:DX
|
0.026x |
|
Momentum Metropolitan Holdings Ltd
JSE:MTM
|
0.051x |
Annual Cash Flow Conversion Efficiency for Pharvaris BV (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pharvaris BV from 2018 to 2025. View PHVS stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $271.27 Million | $-137.07 Million | -0.505x | -12.63% |
| 2024-12-31 | $267.76 Million | $-120.13 Million | -0.449x | -85.17% |
| 2023-12-31 | $384.05 Million | $-93.05 Million | -0.242x | +46.16% |
| 2022-12-31 | $149.26 Million | $-67.16 Million | -0.450x | -106.78% |
| 2021-12-31 | $204.95 Million | $-44.60 Million | -0.218x | +3.05% |
| 2020-12-31 | $95.79 Million | $-21.50 Million | -0.224x | +37.23% |
| 2019-12-31 | $18.67 Million | $-6.68 Million | -0.358x | +54.81% |
| 2018-12-31 | $4.95 Million | $-3.92 Million | -0.791x | -- |
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more